NCT07280572 (RECLAIM) is a Phase 3 clinical trial of Metformin in Post COVID Condition, sponsored by Janneke van de Wijgert.

Who is sponsoring NCT07280572?

NCT07280572 is sponsored by Janneke van de Wijgert.

What drugs are being tested in NCT07280572?

Interventions in NCT07280572: Metformin, colchicine.

What condition does NCT07280572 study?

NCT07280572 studies Post COVID Condition.

Is NCT07280572 still recruiting?

NCT07280572 is currently enrolling by invitation. Last updated 12 December 2025.

Last reviewed 2025-12-12 · How we verify

NCT07280572: RECLAIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RECLAIM Adaptive Platform Trial for PCC Treatments

ENROLLING BY INVITATION Phase 3 Last updated 12 December 2025

What this trial tests

Phase 3 trial testing Metformin in Post COVID Condition in 1,250 participants. Enrolling by invitation.

Timeline

17 February 2025

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	Janneke van de Wijgert
Phase	Phase 3
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,250
Start date	17 February 2025
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	1 location across Netherlands

Drugs / interventions tested

Metformin (metformin) — full drug profile →
colchicine (COLCHICINE) — full drug profile →

Conditions studied

Post COVID Condition — all drugs for Post COVID Condition →

Sponsor

Janneke van de Wijgert — full company profile →

Who can join

18 and older, any sex, with Post COVID Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RECLAIM is a Phase III, multi-domain, randomized, controlled, adaptive platform trial, designed to evaluate efficacy and safety of repurposed medications in patients with post-COVID condition (PCC). The trial started in the Netherlands in February 2025, comparing metformin, colchicine and usual care in an open-label domain. The information in this registration concerns that first domain in the Netherlands. A second domain, comparing minocyclin to a matching placebo, is expected to start in January 2026, also in the Netherlands. Trial-arms, additional domains and implementing countries may be introduced or terminated as the trial progresses. Participation is fully remote, using electronic consenting, video consultations and home delivery of medication. Default IP use is 12 weeks with biweekly online follow-up questionnaires between Day-1 and Week-12, and one final follow-up questionnaire at week-24.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol.
van de Wijgert JHHM, Schoevers JMH, Swarthout TD, Bouwman WJT, et al · · 2026 · PMID 41715140 · DOI 10.1186/s13063-026-09570-1

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other Janneke van de Wijgert trials

Trials by the same sponsor.

NCT03045809 — Women's Improvement of Sexual Health (WISH) Demonstration Project · completed
NCT02459665 — Rwanda Vaginal Microbiota Restoration Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07280572 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janneke van de Wijgert
Last refreshed: 12 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07280572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing